Polysaccharide-protein conjugate vaccination induces antibody production but not sustained B-cell memory in the human nasopharyngeal mucosa

Mucosal Immunology

Volumn 6, Issue 2, 2013, Pages 288-296

  Clarke, E T ^a   Williams, N A ^a   Dull, P M ^b   Findlow, J ^c   Borrow, R ^c   Finn, A ^a   Heyderman, R S ^a,d  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b Clinical Development   (United States)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d UNIVERSITY OF MALAWI   (Malawi)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; DIPHTHERIA VACCINE; IMMUNOGLOBULIN G ANTIBODY; MENINGOCOCCAL NEISSERIA MENINGITIDIS SEROGROUP A POLYSACCHARIDE TETANUS TOXOID CONJUGATE VACCINE; MENINGOCOCCAL NEISSERIA MENINGITIDIS SEROGROUP A POLYSACCHARIDE VACCINE; MENINGOCOCCAL NEISSERIA MENINGITIDIS SEROGROUP ACWY POLYSACCHARIDE CROSS REACTIVE MATERIAL 197 CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL COLONIZATION; CHILD; CONTROLLED STUDY; HERD IMMUNITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; MEMORY CELL; MUCOSAL IMMUNITY; NASOPHARYNGEAL MUCOSA; NORMAL HUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY TRACT MUCOSA; SALIVA ANALYSIS;

EID: 84874060861     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2012.70     Document Type: Article

References (50)

1. Pollard, A. J., Perrett, K. P. & Beverley, P. C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9, 213-220 (2009).
2. Perrett, K. P. et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr. Infect. Dis. J. 28, 186-193 (2009).
3. Snape, M. D. et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299, 173-184 (2008).
4. Maiden, M. C. et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197, 737-743 (2008).
5. Ramsay, M. E., Andrews, N. J., Trotter, C. L., Kaczmarski, E. B. & Miller, E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326, 365-366 (2003).
6. Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055-1065 (2010).
7. Auckland, C. et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J. Infect. Dis. 194, 1745-1752 (2006).
8. Trotter, C. L., Andrews, N. J., Kaczmarski, E. B., Miller, E. & Ramsay, M. E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364, 365-367 (2004).
9. McVernon, J., Mitchison, N. A. & Moxon, E. R. T helper cells and efficacy of Haemophilus influenzae type b conjugate vaccination. Lancet Infect. Dis. 4, 40-43 (2004).
10. Black, S. et al. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine 28, 657-663 (2010).
11. Gasparini, R. et al. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin. Vaccine Immunol. 17, 537-544 (2010).
12. Halperin, S. A., Diaz-Mitoma, F., Dull, P., Anemona, A. & Ceddia, F. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Eur. J. Clin. Microbiol. Infect. Dis. 29, 259-267 (2010).
13. Khatami, A. et al. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine 16, 2831-2838 (2012).
14. Snape, M. D. et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 336, 1487-1491 (2008).
15. Trotter, C. L. et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin. Vaccine Immunol. 15, 1694-1698 (2008).
16. Neutra, M. R. & Kozlowski, P. A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6, 148-158 (2006).
17. Brandtzaeg, P. & Johansen, F. E. Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol. Rev. 206, 32-63 (2005).
18. Quiding-Jarbrink, M. et al. Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J. Clin. Invest. 99, 1281-1286 (1997).
19. Findlow, H. et al. Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults. Clin. Vaccine Immunol. 18, 424-429 (2011).
20. Wing, J. B. et al. Kinetics of immune responses to nasal challenge with meningococcal polysaccharide one year after serogroup-C glycoconjugate vaccination. Clin. Infect. Dis. 52, 1317-1323 (2011).
21. MacPherson, G. G. & Liu, L. M. Dendritic cells and Langerhans cells in the uptake of mucosal antigens. Curr. Top Microbiol. Immunol. 236, 33-53 (1999).
22. Cariappa, A. et al. The recirculating B cell pool contains two functionally distinct, long-lived, posttransitional, follicular B cell populations. J. Immunol. 179, 2270-2281 (2007).
23. Miyasaka, M. & Tanaka, T. Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nat. Rev. Immunol. 4, 360-370 (2004).
24. Martin, F. & Kearney, J. F. B1 cells: similarities and differences with other B cell subsets. Curr. Opin. Immunol. 13, 195-201 (2001).
25. Martin, F. & Kearney, J. F. Marginal-zone B cells. Nat. Rev. Immunol. 2, 323-335 (2002).
26. Pillai, S. & Cariappa, A. The follicular versus marginal zone B lymphocyte cell fate decision. Nat. Rev. Immunol. 9, 767-777 (2009).
27. Balmer, P. et al. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect. Immun. 72, 332-337 (2004).
28. Stoehr, G. A. et al. Mode of splenectomy and immunogenicity of meningococcal vaccination in patients with hereditary spherocytosis. Br. J. Surg. 95, 466-471 (2008).
29. Spencer, J., Perry, M. E. & Dunn-Walters, D. K. Human marginal-zone B cells. Immunol. Today 19, 421-426 (1998).
30. Dono, M. et al. Subepithelial B cells in the human palatine tonsil. II. Functional characterization. Eur. J. Immunol. 26, 2043-2049 (1996).
31. Tsai, T. F. et al. Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection? Clin. Vaccine Immunol. 13, 854-861 (2006).
32. Ala ' Aldeen, D. A. et al. Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination. J. Clin. Microbiol. 38, 2311-2316 (2000).
33. Edwards, E. A., Devine, L. F., Sengbusch, G. H. & Ward, H. W. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand J. Infect. Dis. 9, 105-110 (1977).
34. Goldschneider, I., Gotschlich, E. C. & Artenstein, M. S. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129, 1327-1348 (1969).
35. Sim, R. J., Harrison, M. M., Moxon, E. R. & Tang, C. M. Underestimation of meningococci in tonsillar tissue by nasopharyngeal swabbing. Lancet 356, 1653-1654 (2000).
36. Brandtzaeg, P. & Pabst, R. Let's go mucosal: communication on slippery ground. Trends Immunol. 25, 570-577 (2004).
37. Liu, Y. J. et al. Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid up-regulation of B7-1 and B7-2. Immunity 2, 239-248 (1995).
38. Bernasconi, N. L., Onai, N. & Lanzavecchia, A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101, 4500-4504 (2003).
39. Bernasconi, N. L., Traggiai, E. & Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199-2202 (2002).
40. Guirguis, N. et al. Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies. J. Exp. Med. 162, 1837-1851 (1985).
41. Snapper, C. M. Differential regulation of protein- and polysaccharidespecific Ig isotype production in vivo in response to intact Streptococcus pneumoniae. Curr. Protein Pept. Sci. 7, 295-305 (2006).
42. Wu, Y., Zhang, Q., Sales, D., Bianco, A. E. & Craig, A. Vaccination with peptide mimotopes produces antibodies recognizing bacterial capsular polysaccharides. Vaccine 28, 6425-6435 (2010).
43. Pincus, S. H., Smith, M. J., Jennings, H. J., Burritt, J. B. & Glee, P. M. Peptides that mimic the group B streptococcal type III capsular polysaccharide antigen. J. Immunol. 160, 293-298 (1998).
44. Czerkinsky, C. & Holmgren, J. Topical immunization strategies. Mucosal. Immunol. 3, 545-555 (2010).
45. Lawson, L. B., Norton, E. B. & Clements, J. D. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr. Opin. Immunol. 23, 414-420 (2011).
46. Horton, R. E. et al. Influence of age and carriage status on salivary IgA to Neisseria meningitidis. Epidemiol. Infect. 133, 883-889 (2005).
47. Lal, G., Balmer, P., Joseph, H., Dawson, M. & Borrow, R. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin. Diagn. Lab. Immunol. 11, 272-279 (2004).
48. Davenport, V. et al. Mucosal immunity in healthy adults after parenteral vaccination with outer-membrane vesicles from Neisseria meningitidis serogroup B. J. Infect. Dis. 198, 731-740 (2008).
49. Davenport, V. et al. Evidence for naturally acquired T cell-mediated mucosal immunity to Neisseria meningitidis. J. Immunol. 171, 4263-4270 (2003).
50. Iwajomo, O. H. et al. Deteriorating pneumococcal-specific B-cell memory in minimally symptomatic African children with HIV. J. Infect. Dis. 15, 534-543 (2011).